CompletedNCT00520923
A Multi-Center, Inpatient, Dose Ranging Study of LY2140023 in people with DSM-IV Schizophrenia
Researchers compared LY2140023, placebo and Olanzapine and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Medication studyAges 18–65Multiple countries
Understand this study
What did researchers investigate?
Researchers compared LY2140023, placebo and Olanzapine and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Banfield and 34 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateSeptember 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 669
- Sponsor
- Denovo Biopharma LLC
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Argentina, Austria, Croatia, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00520923
- Official title
Show the full official title
A Multi-Center, Inpatient, Phase 2, Double-blind, Placebo-Controlled Dose Ranging Study of LY2140023 in Patients With DSM-IV Schizophrenia
Get this study by email
Recruitment & locations
CompletedBanfield, Argentina · Buenos Aires, Argentina · Lanus, Argentina
33 more locations
- Munro, Argentina
- Graz, Austria
- Vienna, Austria
- Osijek, Croatia
- Split, Croatia
- Zagreb, Croatia
- Aachen, Germany
- Bochum, Germany
- Dresden, Germany
- München, Germany
- Mexico City, Mexico
- Monterrey, Mexico
- Lisbon, Portugal
- Porto, Portugal
- Bucharest, Romania
- Craiova, Romania
- Iași, Romania
- Târgu Mureş, Romania
- Kazan', Russia
- Khot'kovo, Russia
- Lipetsk, Russia
- Moscow, Russia
- Nikol’skoye, Russia
- Nizhny Novgorod, Russia
- Saint Petersburg, Russia
- Samara, Russia
- Bloemfontein, South Africa
- Cape Town, South Africa
- Durban, South Africa
- Johannesburg, South Africa
- Pretoria, South Africa
- Randburg, South Africa
- Russia
Questions about this study
What did researchers investigate?
Researchers compared LY2140023, placebo and Olanzapine and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who is behind this study?
The study sponsor is Denovo Biopharma LLC.
Did this study involve medication?
Yes. The study involved medication, including LY2140023, Olanzapine and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmit...
A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy